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Abstract
Female patients affected by Fabry disease, an X-linked lysosomal storage disorder, exhibit a wide spectrum of symptoms,
which renders diagnosis, and treatment decisions challenging. No diagnostic test, other than sequencing of the alpha-
galactosidase A gene, is available and no biomarker has been proven useful to screen for the disease, predict disease course
and monitor response to enzyme replacement therapy. Here, we used urine proteomic analysis based on capillary
electrophoresis coupled to mass spectrometry and identified a biomarker profile in adult female Fabry patients. Urine
samples were taken from 35 treatment-naı¨ve female Fabry patients and were compared to 89 age-matched healthy
controls. We found a diagnostic biomarker pattern that exhibited 88.2% sensitivity and 97.8% specificity when tested in an
independent validation cohort consisting of 17 treatment-naı¨ve Fabry patients and 45 controls. The model remained highly
specific when applied to additional control patients with a variety of other renal, metabolic and cardiovascular diseases.
Several of the 64 identified diagnostic biomarkers showed correlations with measures of disease severity. Notably, most
biomarkers responded to enzyme replacement therapy, and 8 of 11 treated patients scored negative for Fabry disease in the
diagnostic model. In conclusion, we defined a urinary biomarker model that seems to be of diagnostic use for Fabry disease
in female patients and may be used to monitor response to enzyme replacement therapy.
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Introduction
Fabry disease (OMIM 301500) is a rare X-linked inherited
lysosomal storage disorder caused by deficient enzymatic activity
of a-galactosidase A (GLA). The resulting defect in the catabolism
of a-D-galactosyl-containing compounds leads to intracellular
accumulation of glycosphingolipids, particularly globotriaosylcer-
amide (Gb3), causing progressive cellular dysfunction. Main
clinical manifestations include: renal disease characterized by
proteinuria along with progressive decline of glomerular filtration
rate (GFR), left ventricular hypertrophy, stroke, acroparesthesia,
hypohidrosis, corneal opacities and angiokeratomas.
Women were previously considered to be mostly asymptomatic
carriers of the disease with mild clinical features. However, it has
recently become evident that some females can experience nearly
all of the symptoms and signs of Fabry disease and may be as
severely affected as men [1]. The high heterogeneity of the Fabry
phenotype in women has been attributed, at least in part, to
random inactivation of one X-chromosome during embryogenesis,
which results in a mosaicism of gene expression with some cells
expressing the functional enzyme and others expressing the
mutated variant [2,3]. The heterogenic Fabry disease phenotype
in women renders both, diagnostic testing and treatment decisions
more challenging than in men.
Diagnosis of Fabry disease in adult male patients is based on
reduced levels of GLA activity in plasma or leukocytes, and
confirmation by genetic mutation analysis [4]. However, in
heterozygous females GLA assays can be inconclusive, showing
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ranges of activity between low to normal levels [5]. Thus, diagnosis
of Fabry disease in women requires mutation analysis based on
direct sequencing of the GLA gene. Although treatment with
enzyme replacement therapy (ERT) is recommended by most
experts for all affected men [6,7], there is less agreement on which
female patients should be treated [8]. While treating all
heterozygous females is not justified given the benign disease
course in many individuals and the high cost of ERT, limiting
ERT to patients with end organ damage would delay therapy to a
point where irreversible damage has already occurred. Lack of a
reliable disease biomarker further hampers individualized therapy
and current dosing recommendations for ERT are relatively
arbitrary, both in men and in women.
Despite continuous efforts to identify Fabry disease biomarkers,
there is still no clearly useful marker. Gb3 accumulation in tissues
and body fluids (urine and plasma) is one candidate biomarker that
has been used for screening [9] and monitoring response to ERT
[10,11]. However, the usefulness of plasma and urinary Gb3 levels
has been questioned [12], and in particular, it was not elevated in
most hemizygous female patients. Thus, reliable biomarkers for
Fabry disease are needed, particularly for female patients.
In our study, we used a proteomic approach to identify bio-
markers in heterozygous adult female Fabry patients. Capillary
electrophoresis coupled to mass spectrometry (CE-MS) is a reliable
high-throughput method to simultaneously measure the excretion
of hundreds of polypeptides and small proteins in the urine [13].
This technique utilizes capillary electrophoresis (CE) to separate
small proteins according to their electrophoretic characteristics,
directly followed by mass spectrometric analysis (MS) by electron
spray ionization (ESI) and time-of-flight mass spectrometry (TOF-
MS). Thus, every detected peptide will be unambiguously
characterized by the migration time in CE and the molecular
mass determined by MS. CE-MS is characterized by a low amount
of sample required, a short analysis time and a high reproducibility
owing to the constant buffer composition and flow characteristics
of CE that allow stable ESI conditions for coupling to MS
throughout the run. Using CE-MS, a total of over 100,000
different peptides have been detected in human urine, and 5,000
of those are detectable in at least 20% of urine samples [14],
rendering CE-MS based urine proteomic analysis a powerful tool
for the discovery of potential biomarkers. Here, we used CE-MS of
urine to identify a proteomic pattern that characterizes female
Fabry patients.
Results
Patient characteristics
We examined a total of 52 treatment-naı¨ve and 11 ERT treated
adult female Fabry patients from three clinical centers. The
untreated patients were randomly divided in a 2:1 ratio into a
training cohort and a validation cohort. Clinical characteristics of
these two cohorts and the patients under ERT are given in
Table 1. Patient characteristics did not differ among centers (data
not shown). Overall, patients had relatively few symptoms and well
preserved renal and cardiac functions. The Mainz Severity Score
Index (MSSI) [15] was available for 19 patients of the training
cohort (median 9.0, range 0–24) and 8 patients of the validation
cohort (median 6.5, range 1–16).
Fabry disease is characterized by a unique urinary
biomarker profile
The compiled data of the CE-MS analysis of all urine samples
from the 35 untreated female Fabry patients and the 89 age-
matched female healthy controls of the training cohort are shown in
Figure 1 a and b, respectively. The comparison of the abundance
of individual urinary peptides between patients and controls resulted
in the identification of 152 peptides with significantly altered urinary
Table 1. Clinical characteristics of all studied female Fabry patients.
cohort training validation ERT
N 35 17 11
age (years) 40.9612.6 35.7612.8 36.4616.4
renal manifestations
GFR (ml/min/1.73 m2) 87623 91613 85620
urine protein (mg/g crea), median (range) 65 (20–1364) 59 (44–1248) 55 (50–195)
urine albumin (mg/g crea), median (range) 14 (3–864) 10 (5–258) 8 (5–106)
microalbuminuria, N (%) 7 (21%) 4 (24%) 1 (9%)
macroalbuminuria, N (%) 3 (9%) 0 (0%) 0 (0%)
cardiac manifestations
LVMI (g/m2) 83629 81619 111677
LVH, N (%) 5 (14%) 1 (6%) 3 (27%)
arrhythmia, N (%) 1 (3%) 0 (0%) 0 (0%)
nervous system involvement
stroke, N (%) 2 (6%) 0 (0%) 2 (18%)
acroparesthesia, N (%) 13 (41%) 8 (47%) 11 (100%)
other manifestations
angiokeratoma, N (%) 4 (13%) 2 (12%) 1 (9%)
hypohydrosis, N (%) 6 (19%) 1 (6%) 4 (36%)
ERT, enzyme replacement therapy; GFR, glomerular filtration rate; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy (defined as LVMI$110 g/m2). Data
are mean 6 SD, unless otherwise stated.
doi:10.1371/journal.pone.0020534.t001
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excretion (adjusted p-value,0.05). The CE-MS characteristics of
these markers and their regulation in Fabry disease are given in
Table S1. Due to the fact that the number of potential biomarkers
exceeded the number of samples studied, we attempted to identify
the most consistent markers by randomly excluding 30% of all
patients and controls from the analysis. After repeating this analysis
30 times as an iterative algorithm, we chose only those 64 markers
that significantly differed between patients and controls in at least
50% of all permutations. Based on these 64 markers (Figure 1 c
and d) we next created a support-vector-machine (SVM)-based
model to distinguish Fabry patients from controls. The SVM-based
model combines the amplitude of all 64 markers for a given urine
sample into a score, which denotes the distance of that sample in a
64-dimensional space (every dimension representing the amplitude
of one marker) from a hyperplane that is designed to separate the
cases from controls. This model correctly classifies all cases and
Figure 1. Compiled urinary protein profiles of female Fabry patients (a) and healthy controls (b) included in the training cohort.
Normalized MS molecular weight (800–20,000 Da) in logarithmic scale is plotted against normalized CE migration time (18–45 min). The mean signal
intensity of polypeptides is given as peak height. 3-D contour plots of the 64 diagnostic markers in the Fabry (c) and healthy control (d) patient
cohort with 56 zoom compared to (a) and (b).
doi:10.1371/journal.pone.0020534.g001
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controls in the training cohort, corresponding to an area under the
receiver-operator-characteristics curve (AUC) of 1. Complete take-
one-out crossvalidation in the training cohort yielded an AUC of
0.939 (95% CI 0.882–0.974) (Figure 2 a). We then tested the
diagnostic model in an independent validation cohort consisting of
17 untreated female Fabry patients and 45 age- and sex-matched
healthy controls. Using as a diagnostic cut-off value the mean
between the highest and lowest possible cut-off values that would
yield 100% sensitivity and 100% specificity in the training cohort,
the model achieved a sensitivity of 88.2% and a specificity of 97.8%
in the validation cohort (AUC 0.970, 95% CI 0.891–0.996)
(Figure 2 b) using genetic mutation analysis as a reference. The
two Fabry patients from the validation cohort with false-negative
proteomic test results did not obviously differ from the remaining
patients, in particular they had both GLAmutations which were not
unique in the cohort (one missense and one nonsense mutation).
To further evaluate the specificity of the biomarker model for
Fabry disease as compared to other disorders, we applied it to a
total of 412 previously analyzed urine probes from female patients
suffering from a wide variety of renal, metabolic and cardiovas-
cular diseases. The overall specificity of the model applied to these
412 patients was 97%, i.e. the rate of false positive results for Fabry
disease among patients with other diseases was very low (Table 2).
To gain insight into pathophysiologic mechanisms, we attempt-
ed to identify the peptides with altered excretion in Fabry disease.
Because the small sample volume used for capillary electrophoresis
is not usually sufficient for tandem mass spectrometry based
sequencing, we used liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) for peptide sequencing. We were able to
identify the amino acid sequence of 50 out of all 152 differentially
excreted peptides, and among the 64 markers used in the
diagnostic model, 13 could be identified. The peptide sequences
of all identified markers are given along with their CE-MS
characteristics in Table S1. The majority of identified regulated
peptides were collagen fragments with 2/3 of them being up- and
1/3 being downregulated. Interestingly, the C-terminal sequences
PPG and PGP were very frequent among the upregulated
fragments (6/24 and 11/24, respectively), whereas they were
hardly present among the downregulated (0/12 and 1/12,
respectively).
Correlation of biomarkers with disease severity and
progression
We wondered whether the proteomic changes could reflect
disease severity and predict progression in addition to a potential
diagnostic use. We therefore correlated the intensity of all 64
diagnostic biomarkers with GFR, albuminuria, and left ventricular
mass index (LVMI) in the total treatment-naı¨ve study population
consisting of the training and validation cohorts. As a measure of
disease progression, we calculated GFR slope by regressing
estimated GFR over time for every patient. Follow-up serum
creatinine measurements were available for 36 patients. In these
36 patients, an average of 3.6 (range: 2–7) creatinine measure-
ments were available over a mean period of 3.561.9 years
(1.861.7 years before and 1.761.4 years after urine sampling for
CE-MS analysis). In the unadjusted analysis, several markers
showed significant correlations with these clinical measures of
disease severity (6 with GFR, 6 with albuminuria, and 11 with
LVMI). However, after adjustment for multiple testing, only two
correlations remained significant (both with GFR).
Effects of enzyme replacement therapy on the biomarker
profile
To analyze the effects of enzyme replacement therapy on the
urine proteome in Fabry disease, we analyzed spot urine samples
of 11 female Fabry patients that were receiving ERT. The clinical
characteristics of these patients are summarized in Table 1.
Notably, the treated patients did not differ significantly in terms of
their clinical parameters from the untreated patients except for a
higher rate of reported acroparesthesia (p,0.001). In particular,
GFR, albuminuria and LVMI were not significantly different.
Their median MSSI was 11 (range 5–30) and tended to be higher
than in the untreated patients. Details on the type of ERT product,
duration and dose, and timing of urine sampling relative to ERT
are given in Table 3.
The compiled proteomic data of all treated patients are
graphically depicted in Figure 3 a. Of the 64 biomarkers
(Figure 3 b) from the diagnostic model, 31 differed significantly
between treated and untreated (training and validation cohort)
patients in the unadjusted analysis and 16 remained significant
after adjustment for multiple testing. The mean levels of all of
these biomarkers were changed toward their mean levels in
healthy control subjects. Importantly, when applying the diagnos-
tic biomarker model to the treated patients, only three out of 11
scored positive. Thus, ERT seams to have a profound effect on the
urinary proteome, changing it toward that of healthy controls. The
3 ERT treated patients who still scored positive for Fabry disease
did not significantly differ from the remaining 8 in terms of
treatment duration (4.162.1 vs. 3.462.3 years, p = 0.557) or time
interval between the last ERT infusion and urine sampling for
Figure 2. ROC curves for differentiation of Fabry female patients and female healthy controls in the training set upon complete
take-one-out crossvalidation (a) and in the independent validation set (b).
doi:10.1371/journal.pone.0020534.g002
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proteomic analysis (7.064.4 vs. 10.068.3 days, p = 0.364),
although one of them received only a reduced dose of ERT.
Discussion
We have identified and validated a distinct peptide profile in the
urine that characterizes adult female Fabry patients. This pattern
distinguishes female Fabry patients from healthy controls and from
patients with various other forms of kidney or systemic diseases
and responds to ERT.
Until now, no study demonstrated the usefulness of a bio-
marker in adult female Fabry patients as diagnostic marker or as a
surrogate marker for disease severity and ERT response. Proteomic
techniques offer an unbiased approach to discover unanticipated
biomarkers. In addition, the simultaneous detection of hundreds of
polypeptides allows for the definition of proteomic biomarker
patterns (proteomic profiling), rather than single biomarkers. We
used urine rather than serum or plasma for proteomic analysis due
to several advantages of urine as sample source that have been
discussed in detail elsewhere [16,17]: First, blood contains a high
dynamic range between low-level and highly abundant proteins.
Removal of highly abundant proteins, such as albumin, which
would otherwise obscure the detection of low-level proteins, leads to
a concommitant loss of other proteins due to their binding to
albumin or unspecific interaction with the affinity column. Second,
urine is relatively stable in its composition if handled properly,
which may be in part explained by the completion of endogenous
proteolysis at the time of urine voidance. Blood, in contrast, contains
high level of endogenous protease activity. Third, urine normally
does not contain relevant amounts of cellular elements, obviating
the need for preanalytical separation. Finally, urine is enriched in
low-molecular-weight proteins and peptides, which can be trans-
ferred without an initial protease digestion step directly to protein
mass spectrometry (top-down MS). Compared to other methods of
proteomic analysis, such as 2-dimensional gel electrophoresis
(2DGE) or liquid chromatography (LC) followed by mass
spectrometry, CE-MS has the advantage of robustness, high
reproducibility, low sample volume required, and short analysis
time, which make it particularly suitable for clinical proteomic
profiling.
Two studies have been previously published that used a
proteomic approach to biomarker discovery in Fabry disease.
Moore et al. [18] compared serum samples of 12 male and 1
female pediatric Fabry patients before and after 6 months of ERT
by LC-MS/MS and found 5 of 50 identified proteins to be
significantly altered under therapy. Vojtova et al. [19] compared
11 male and 9 female Fabry patients with or without ERT to 10
healthy controls using 2DGE followed by MALDI-TOF/TOF
and identified 5 differentially expressed proteins. However, none
of the above mentioned studies validated their results in an
independent cohort. Given the large number of peptides being
simultaneously detected using proteomic techniques, vigorous
adjustment for multiple testing and validation of the results in an
Table 2. Specificity of the biomarker model for differentiating
Fabry disease from other renal, metabolic and cardiovascular
diseases.
Disease Age
False posi-
tive/total N
Specifi-
city (%)
ADPKD 3168 6/78 92
diabetic nephropathy 58613 0/47 100
FSGS 42623 0/27 100
heart failure 68610 1/9 89
hypertension 66611 1/17 94
IgA nephropathy 35613 0/24 100
cardiovascular disease 6667 3/47 94
minimal change disease 42610 0/12 100
membranous nephropathy 54620 0/9 100
kidney stones 5668 0/8 100
renal cell carcinoma 64611 0/42 100
bladder cancer 66611 4/46 91
systemic lupus erythematodes 41611 0/19 100
ANCA vasculitis 6766 0/27 100
ADPKD, autosomal dominant polycystic kidney disease; FSGS, focal segmental
glomerulosclerosis; ANCA, anti-neutrophil cytoplasmic antibodies. Data are
mean 6 SD, unless otherwise stated.
doi:10.1371/journal.pone.0020534.t002
Table 3. Duration, dose and timing of ERT in the analyzed treated patients.
age (years)
body
weight (kg)
ERT product and
dose/2 weeks
interval from last
ERT dose to urine
sampling (days)
treatment
duration (years)
biomarker
score
62 72 agalsidase alfa 0.22 mg/kg 13 0.6 21.999 (neg)
28 60 agalsidase alfa 0.18 mg/kg 1 3.6 21.436 (neg)
25 49 agalsidase alfa 0.21 mg/kg 7 3.8 21.129 (neg)
17 51 agalsidase alfa 0.20 mg/kg 13 2.4 20.601 (neg)
43 51 agalsidase alfa 0.28 mg/kg 5 1.1 20.563 (neg)
59 52 agalsidase alfa 0.20 mg/kg 2 5.6 20.313 (neg)
22 59 agalsidase alfa 0.20 mg/kg 7 5.6 20.245 (neg)
34 63 agalsidase alfa 0.22 mg/kg 6 0.1 0.060 (neg)
33 55 agalsidase beta 1.27 mg/kg 13 6.4 0.241 (pos)
20 45 agalsidase alfa 0.20 mg/kg 1 5.9 0.316 (pos)
57 58 agalsidase alfa 0.12 mg/kg 17 2.3 0.455 (pos)
ERT, enzyme replacement therapy. The diagnostic cut off value for the biomarker score is 0.1.
doi:10.1371/journal.pone.0020534.t003
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independent cohort are of particular importance [20]. Our study
is, to our knowledge, the first proteomic study in Fabry disease,
which compares both, treatment-naı¨ve and ERT treated patients
to healthy controls and validated the results in an independent
cohort.
The biomarker model that we describe distinguishes adult
untreated female Fabry patients not only from age-matched
healthy controls but also from a large number of different renal
diseases with a high degree of specificity. This makes CE-MS
particularly useful as a noninvasive diagnostic screening test in
unexplained renal, cardiac or cerebrovascular disease. Several
recent studies have shown a high prevalence of Fabry disease in
populations with unexplained renal failure [21,22,23,24], stroke
[25,26,27] or hypertrophic cardiomyopathy [28,29,30]. However,
screening these populations for Fabry disease is hampered by the
low sensitivity of GLA activity measurement in female patients
(50% [31]–67% [32]) whereas diagnostic sequencing of the GLA
gene is not feasible given the high cost (currently ca. 2,000–3,000
USD). CE-MS is available for clinical use and considerably
cheaper than genetic testing (currently ca. 500 USD, i.e. similar to
the price of GLA activity assays). In terms of diagnostic accuracy,
CE-MS also favourably compares to urinary Gb3, for which an
AUC of 0.876 has been reported [33] (vs. 0.970 for CE-MS in our
study), although lyso-Gb3 seems to perform better than total Gb3
[34]. In addition, because similarly accurate CE-MS based
diagnostic models have been developed for a variety of other
renal and cardiovascular diseases [13,35,36,37,38,39], CE-MS
may give hints to an alternative diagnosis in Fabry negative
patients, i.e. this approach may offer an efficient diagnostic
method, which can detect a variety of diseases using a single
diagnostic test. With 97.8%, specificity was high, thus reducing the
false positive rate if screening preselected patients. Certainly, the
specificity is not ideal, and as a consequence, to avoid high false
positive rates, CE-MS is not suitable for screening women at very
low risk for Fabry disease, e.g. the general population. Also,
mutation analysis will be required for diagnostic confirmation, in
particular before initiating a costly therapy. In summary, CE-MS
as a diagnostic tool for Fabry disease in females may be clinically
useful primarily in the evaluation of patients with unexplained
renal disease, hypertrophic cardiomyopathy or cerebrovascular
disease, followed by mutation analysis for patients scoring positive
in CE-MS.
Importantly, most ERT treated female Fabry patients scored
negative in the diagnostic model. Thus, ERT seems to reduce the
Fabry-specific alterations in the urinary polypeptide pattern to a
level below the diagnostic threshold in most patients receiving
ERT. Hence, CE-MS could be useful for monitoring response to
treatment, i.e. lack of the urine proteome to normalize may be an
indicator of insufficient dosing of ERT. This finding is noteworthy,
as ERT dosing recommendations are largely arbitrary to date.
Further studies are needed to determine whether the response of
the urine proteomic profile to ERT is of prognostic value and
whether it is dose-dependent. Given that treated and untreated
patients were similar with respect to their end-organ manifesta-
tions, reversibility of proteomic alterations under therapy indicates
that these alterations probably reflect ongoing pathophysiological
processes rather than established organ damage. Thus, it is likely
that the changes in the urine proteome that we identified are both
dose-dependent and may be of prognostic value as they mirror
disease activity.
We found correlations with disease severity for only a minority
of the diagnostic biomarkers, which may be explained by a
number of reasons: First, the diagnostic markers were selected
with the aim to achieve a high sensitivity and specificity. Thus,
only robust markers that were altered in most patients have been
included in the model and these markers may not be the most
Figure 3. Compiled urinary protein profiles of ERT treated female Fabry patients (a). Normalized MS molecular weight (800–20,000 Da) in
logarithmic scale is plotted against normalized CE migration time (18–45 min). The mean signal intensity of polypeptides is given as peak height.
(b) 3-D contour plots of the 64 specific markers in the treated Fabry cohort with 56 zoom compared to (a). Note that the proteomic pattern
resembles more that of healthy controls (Figure 1b and d) than that of untreated female Fabry patients (Figure 1a and c).
doi:10.1371/journal.pone.0020534.g003
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useful for a severity score. Second, most included patients had few
manifestations of Fabry disease and the study cohort did not
cover the whole spectrum of disease severity. Third, most variables
used to assess disease severity may be affected by factors other
than Fabry disease and show a considerable variation even in
healthy subjects. Fourth, clinical measures of disease severity
mostly reflect irreversible organ damage, whereas many diagnos-
tic pattern biomarkers, as stated above, responded to treatment
and thus did not reflect irreversible organ damage. Further
studies using larger patient cohorts, including a broader spectrum
of disease severity as well as longer follow up time, will be needed
to define prognostic markers and to generate a prognostic
biomarker model.
Sequencing of naturally occurring peptides by MS/MS still
represents a challenge [17]. We were able to identify nearly one
third of differentially excreted peptides. Similar to other diseases
that have been studied using CE-MS [35,36,38,39,40], most
diagnostic biomarkers identified represent collagen fragments.
Indeed, collagen fragments appear to be the major constituents of
urinary peptides identified to date [39]. The predominance of
collagen fragments among identified urinary peptides may be
somewhat biased due to the fact that they are more easily
fragmented and detected by MS/MS owing to their high content
in proline residues. Nevertheless, urinary collagen fragments likely
reflect a high normal physiological turnover of the extracellular
matrix that may be altered in disease. Of note, most collagen
fragments upregulated in female Fabry disease exhibited one of
two characteristic C-terminal motivs, PPG or PGP. This particular
pattern seems relatively specific for Fabry disease. Further study is
needed to test whether these fragments arise from cleavage by a
particular type of protease. It is tempting to speculate that
lysosomal proteases, such as cathepsins, are released in Fabry
disease due to lysosomal accumulation of Gb3 and lead to cleavage
of collagen. Among the other identified peptides, 6 were
uromodulin fragments, all of which were upregulated. Interest-
ingly, these were all C-terminal fragments. It has previously been
shown that Fabry patients excrete reduced amounts of full-length
uromodulin but abnormally processed uromodulin lacking the C-
terminus [41]. Efforts to sequence the remaining urinary
polypeptides are ongoing and may in the future provide additional
pathopysiological insights.
We have limited the analysis to adult female Fabry patients,
because we felt that biomarkers to guide diagnosis and treatment
decisions are particularly needed for in this patient subgroup.
Furthermore, we focused on Fabry patients with relatively few
manifestations, aiming to identify markers of early disease
progression. Future work will address the use of urine proteomics
in both, adult male Fabry patients and in children.
In summary, we defined a urinary biomarker model that allows
diagnostic evaluation of female patients for Fabry disease with
high accuracy and might be used to monitor response to ERT.
Further study is needed to identify prognostic markers and to
establish a dose-response relationship between ERT and urinary
peptide changes.
Methods
Ethics Statement
Collection of patient data and collection, storage and analysis of
urine samples have been approved by the local ethics committees
of the three participating centers (Kantonale Ethikkommission
Zu¨rich, Ethik-Kommission bei der Medizinischen Fakulta¨t der
Universita¨t Wu¨rzburg, and Royal free Hospital and Medical
School research ethics committee, respectively). All participating
subjects gave written informed consent. This study was performed
in accordance with the Helsinki Declaration.
Patients and Procedures
52 treatment-naı¨ve and 11 ERT-treated female Fabry patients
from three clinical centers were studied. The diagnosis of Fabry
disease was confirmed by mutation analysis in all patients. Control
urine samples were taken from healthy volunteers and patients
with a variety of other renal, metabolic and cardiovascular
diseases. These samples have been previously collected as part of
several clinical studies (refs [13,35,36,37,38,39] and as yet
unpublished studies). All samples were collected in the morning
from midstream urine, frozen at 220uC without prior centrifu-
gation and without addition of protease inhibitors, as suggested in
recently published recommendations [42].
Sample preparation and CE-MS analysis
All urine samples for CE-MS analyses were stored in ac-
cordance with current recommendations of EuroKUP and
HUPO/HKUPP (http://www.eurokup.org/sites/default/files/
StandardProtocolforUrine Collection.pdf) at 220uC until analysis
and underwent a maximum of 2 freeze/thaw cycles. A 0.7 mL
aliquot was thawed immediately before use, diluted with 0.7 mL of
2 M urea, 10 mM NH4OH and 0.02% SDS, filtered using
Centrisart ultracentrifugation filter devices (20 kDa MWCO;
Sartorius, Goettingen, Germany) at 3,000 g until 1.1 ml of filtrate
was obtained and desalted on a PD-10 desalting column
(Amersham Bioscience, Uppsala, Sweden) equilibrated in 0.01%
NH4OH in HPLC-grade H2O. Finally, all samples were
lyophilized, stored at 4uC, and resuspended in HPLC-grade
H2O shortly before CE-MS analysis.
CE-MS analysis was performed as described previously [13,43]
using a P/ACE MDQ capillary electrophoresis system (Beckman
Coulter, Fullerton, USA) on-line coupled to a Micro-TOF MS
(Bruker Daltonic, Bremen, Germany). The ESI sprayer (Agilent
Technologies, Palo Alto, CA, USA) was grounded, and the ion
spray interface potential was set between 24 and 24.5 kV. Data
acquisition and MS acquisition methods were automatically
controlled by the CE via contact-close-relays. Spectra were
accumulated every 3 s, over a range of m/z 350 to 3000. Accuracy,
precision, selectivity, sensitivity, reproducibility, and stability of the
analytical platform were demonstrated and described in great detail
elsewhere [13].
Data processing, cluster analysis and statistical methods
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisu software [44]. Migration time and ion signal
intensity (amplitude) were normalized using internal polypeptide
standards [45,46]. For the identification of potential biomarkers,
the reported p-values were calculated using the Wilcoxon Rank-
Sum test followed by adjustment for multiple testing using the
method described by Benjamini and Hochberg [47]. Disease-
specific polypeptide patterns were generated using SVM based
MosaCluster software [48]. Sensitivity and specificity were
calculated based on tabulating the number of correctly classified
samples. Confidence intervals (95% CI) based on exact binomial
calculations were carried out in MedCalc version 8.1.1.0
(MedCalc Software, Mariakerke, Belgium, http://www.medcalc.
be). The Receiver Operating Characteristic (ROC) plot was
obtained by plotting all sensitivity values on the y-axis against their
equivalent 1-specificity values on the x-axis for all available
thresholds (MedCalc Software). The AUC was evaluated, as it
provides a single measure of overall accuracy that is not dependent
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upon a particular threshold [49]. To correlate individual
biomarkers with measures of disease severity or with response to
treatment, Kendall Tau and Mann-Whiney U-test were used,
respectively, and adjustment for multiple testing was done using
the Bonferroni correction.
Sequencing of polypeptides
Some of the candidate biomarkers have been previously
sequenced using liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) analysis as recently described in detail
[50]. We further tried to identify as yet unidentified urinary
peptides that were regulated in Fabry disease. ESI LTQ-OT MS
using HCD (higher collisional dissociation) was performed on a
LTQ Orbitrap XL equipped with a NanoAcquity system from
Waters. Peptides were trapped on a home-made 5 mm 200 A˚
Magic C18 AQ (Michrom) 0.1620 mm pre-column and separated
on a home-made 5 mm 100 A˚ Magic C18 AQ (Michrom)
0.756150 mm column with a gravity-pulled emitter. The
analytical separation was run for 65 min using a gradient of
H2O/FA 99.9%/0.1% (solvent A) and CH3CN/FA 99.9%/0.1%
(solvent B) as follows: 0–1 min 95% A and 5% B, then to 65% A
and 35% B at 55 min, and 20% A and 80% B at 65 min at a flow
rate of 220 nL/min. For MS survey scans, the OT resolution was
set to 60000 and the ion population was set to 5E5 with an m/z
window from 400 to 2000. Three precursor ions were selected for
collision-induced dissociation in the supplementary hexapole prior
to Orbitrap analysis. For this, the ion population was set to 2E5,
with an isolation width of 2.5 m/z units. The normalized collision
energies were set to 40%. Spectral data was converted into .dta
files (RAW files generated by ion traps from Thermo Fisher
Scientific) and searched against human entries in the Swiss-Prot
database (Swiss-Prot Number 2010.06) using the Open Mass
Spectrometry Search Algorithm (OMSSA; free from NCBI,
http://pubchem.ncbi.nlm.nih.gov/omssa/); e-value cut-off was
0.01. All matched sequences were manually validated.
Supporting Information
Table S1 CE-MS characteristics of all urinary peptides
that significantly differed between female Fabry pa-
tients and controls with sequence information of
identified peptides; peptides that were used in the
diagnostic biomarker model are depicted in bold.
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